{
  "report_rows": [
    {
      "kpi": "Q2 2026 Organic Revenue Growth",
      "prediction": "IN-LINE",
      "answer": "pred ~5.5% organic growth vs. cons 5.3%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.84 vs. cons $0.83",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "WATCHMAN Global Sales Growth (Q2)",
      "prediction": "MISS",
      "answer": "pred ~9% growth vs. cons ~11-12% (implied by mgmt's 'flat Q1-to-Q2 dollars' framing and mid-teens FY guide)",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Organic Revenue Growth Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~6.5%-8% (reaffirmed, ~7% implied midpoint) vs. cons ~7.0% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adjusted EPS Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.34-$3.41 (reaffirmed, ~$3.37 midpoint) vs. cons ~$3.38 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 Organic Revenue Growth (implied next-quarter guide)",
      "prediction": "LOWER",
      "answer": "guide ~6.0% vs. cons ~6.8% (Q3 2026, reflecting continued WATCHMAN/EP softness flagged as 'likely flat into Q3')",
      "confidence": "LOW"
    },
    {
      "kpi": "Restructuring Savings Flow-Through to 2026/2027 EPS",
      "prediction": "UNKNOWN",
      "answer": "guide ~modest/limited 2026 benefit (~$0.00-0.02 EPS) vs. cons assuming ~$0.03-0.05 EPS accretion (FY2026-27 ramp)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.0,
  "day5_path": "FADE",
  "day5_rationale": "Bar is extremely low after three guidance cuts and a >50% YTD decline, so an in-line quarter with reaffirmed FY guidance and credible restructuring detail likely sparks a relief rally on day 1 (short covering, oversold bounce already visible into the print). But out-period math works against follow-through: WATCHMAN standalone and EP/Farapulse trends are still described as pressured into Q3, Urology turnaround is unproven, and the pending Penumbra deal (financing/integration) remains an overhang not yet in guidance. As analysts rebuild 2H26/2027 models they will likely trim WATCHMAN and EP segment assumptions even if headline organic/EPS were in-line, causing the initial pop to partially fade over the week as the 'third cut risk' narrative resurfaces heading into Q3 print positioning.",
  "day5_confidence": "MEDIUM"
}